Rainer Maria Bohle
Overview
Explore the profile of Rainer Maria Bohle including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
428
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pohlers M, Gies S, Taenzer T, Stroeder R, Theobald L, Ludwig N, et al.
Mol Oncol
. 2023 Oct;
18(9):2157-2178.
PMID: 37899663
During cervical carcinogenesis, T-helper (Th)-17 cells accumulate in the peripheral blood and tumor tissues of cancer patients. We previously demonstrated that Th17 cells are associated with therapy resistance as well...
2.
Flockerzi F, Hohneck J, Langer F, Bohle R, Stahl P
Int J Mol Sci
. 2023 Jul;
24(13).
PMID: 37445817
Lung cancer is the leading cause of cancer-related deaths in the western world, with squamous cell carcinoma being one of the most common histological subtypes. Prognostic and predictive markers are...
3.
Flockerzi F, Hohneck J, Saar M, Bohle R, Stahl P
Diagnostics (Basel)
. 2023 Jul;
13(13).
PMID: 37443605
Prostate cancer is one of the most common malignancies worldwide, showing a wide range of clinical behaviors. Therefore, several treatment options arise out of the diagnosis "prostate cancer". For this...
4.
Thurner L, Fadle N, Regitz E, Roth S, Cetin O, Kos I, et al.
Haematologica
. 2023 May;
108(12):3347-3358.
PMID: 37139600
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a Hodgkin lymphoma expressing functional B-cell receptors (BCR). Recently, we described a dual stimulation model of IgD+ lymphocyte-predominant cells by Moraxella catarrhalis antigen RpoC...
5.
Flockerzi F, Hohneck J, Saar M, Bohle R, Stahl P
Diagnostics (Basel)
. 2023 Jan;
13(2).
PMID: 36673031
Prostate cancer is one of the most common malignancies, and there are a wide range of treatment options after diagnosis. Most prostate cancers behave in an indolent manner. However, a...
6.
Bock T, Bewarder M, Cetin O, Fadle N, Regitz E, Schwarz E, et al.
EJHaem
. 2022 Sep;
3(3):739-747.
PMID: 36051037
Burkitt lymphoma (BL) represents the most aggressive B-cell-lymphoma. Beside the hallmark of -translocation, surface B-cell receptor (BCR) is expressed, and mutations in the BCR pathway are frequent. Coincidental infections in...
7.
Schmidt G, Guhl M, Solomayer E, Wagenpfeil G, Hammadeh M, Juhasz-Boess I, et al.
Arch Gynecol Obstet
. 2022 Apr;
306(5):1689-1695.
PMID: 35377046
Background: PD-L1 receptor expression in breast cancer tissue can be assessed with different anti-human PD-L1 monoclonal antibodies. The performance of three specific monoclonal antibodies in a head-to-head comparison is unknown....
8.
Theobald L, Stroeder R, Melchior P, Iordache I, Tanzer T, Port M, et al.
Mol Oncol
. 2021 Sep;
15(12):3559-3577.
PMID: 34469022
Cervical cancer therapy is still a major clinical challenge, as patients substantially differ in their response to standard treatments, including chemoradiotherapy (CRT). During cervical carcinogenesis, T-helper (Th)-17 cells accumulate in...
9.
Onken T, Gao L, Orth P, Cucchiarini M, Bohle R, Rupf S, et al.
Clin Transl Med
. 2020 Dec;
10(8):e230.
PMID: 33377646
No abstract available.
10.
Thurner L, Bewarder M, Rosar F, Orth P, Meuter R, Rixecker T, et al.
Hemasphere
. 2020 Dec;
5(1):e511.
PMID: 33324955
No abstract available.